Neuromyelitis Optica Spectrum Disorder Clinical Trial
Official title:
A Prospective, Self-controlled Study to Explore Efficacy and Safety of Orelabrutinib in AQP4-IgG Positive Neuromyelitis Optica Spectrum Disorder
Neuromyelitis optica spectrum disorder (NMOSD) is a chronic inflammatory demyelinating autoimmune disease of the central nervous system. NMOSD is a highly relapsing, severely disabling disease. AQP4-IgG positive NMOSD is related to a specific aquaporin 4 antibody (AQP4 IgG) produced by mature B cells. BTK is a key kinase in B cell receptor signal transduction pathway. Abnormal activation of BTK related signaling pathway can lead to autoantibody production and autoimmune diseases. Therefore, BTK can be developed as a new target for autoimmune diseases.
Approximately 23 subjects will be enrolled. Experimental drug treatment: Orelabrutinib, 50mg, orally, once a day. The subject will come to visit at week 0, 1, 2, 4, 8, 12, 16, 20, 24, 36, 48 and safety follow up visit which is planed 28 days after last administration. Baseline patient assessment: 1. Baseline examination: vital signs, physical examination, blood routine examination, urine routine examination, liver and kidney function, coagulation function, thyroid function, HIV, HCV, HBV virus test, tuberculosis test, chest X-ray, ECG and pregnancy test. 2. Functional disability assessment: Expanded Disability Status Scale (EDSS) score and low contrast vision (LCVA) score. 3. EQ5D scale evaluation. 4. Serum AQP4-IgG titer, neuro filament light chain, T/B/NK cell count, Immunoglobulin (IgG, IgA and IgM) ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04561557 -
Safety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Inflammatory Diseases of the Nervous System
|
Early Phase 1 | |
| Completed |
NCT03002038 -
Comparison of Clinical Effects of Azathioprine and Rituximab NMO-SD Patients
|
Phase 2/Phase 3 | |
| Not yet recruiting |
NCT04064944 -
Comparison of the Efficacy and Safety of Immunoadsorption and Plasma Exchange for Acute Attack of Refractory Neuromyelitis Optica Spectrum Disorders
|
Phase 2 | |
| Recruiting |
NCT05414487 -
Effects of Ofatumumab Treatment on Immune Cells and Meningeal Lymphatic Drainage in Patients With Demyelinating Diseases
|
||
| Not yet recruiting |
NCT05551598 -
Efficacy and Safety of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Neuromyelitis Optica Spectrum Disorder (NMOSD)
|
Phase 2 | |
| Recruiting |
NCT05403138 -
Safety and Efficacy of Daratumumab in Patients With Anti-Aquaporin 4 Antibody Positive Neuromyelitis Optica Spectrum Disorders
|
Phase 2/Phase 3 | |
| Completed |
NCT01845584 -
Phase II Clinical Trial of NPB-01 in Patients With Anti-aquaporin 4 Antibody Positive Neuromyelitis Optica Spectrum Disorder Not Provided Adequate Effect of Therapy to Steroids Plus Therapy.
|
Phase 2 | |
| Active, not recruiting |
NCT04660539 -
A Study to Evaluate the Safety and Efficacy of Satralizumab in Participants With Neuromyelitis Optica Spectrum Disorder (NMOSD)
|
Phase 3 | |
| Recruiting |
NCT05199688 -
A Study To Evaluate Pharmacokinetics, Efficacy, Safety, Tolerability, And Pharmacodynamics Of Satralizumab In Pediatric Patients With Aquaporin-4 Antibody Positive Neuromyelitis Optica Spectrum Disorder (NMOSD)
|
Phase 3 | |
| Recruiting |
NCT05504694 -
Ofatumumab in AQP4-IgG Seropositive NMOSD
|
Phase 1/Phase 2 | |
| Completed |
NCT01777412 -
Efficacy of Bevacizumab (Avastin) in Treatment of Acute NMO Exacerbations
|
Phase 1 | |
| Recruiting |
NCT01623076 -
The Longitudinal CONQUER Study of Rare Neuroimmunologic Disorders
|
||
| Completed |
NCT01500681 -
Maintenance Plasma Exchange for Neuromyelitis Optica
|
||
| Not yet recruiting |
NCT06374264 -
Acceptability and Safety of MR-C-014 in Persons With Neuromyelitis Optica Spectrum Disorder
|
N/A | |
| Recruiting |
NCT05346354 -
Efficacy and Safety Study of Ravulizumab IV in Pediatric Participants With NMOSD
|
Phase 2/Phase 3 | |
| Not yet recruiting |
NCT05891379 -
Inebilizumab in Acute Neuromyelitis Optica Spectrum Disorders
|
||
| Recruiting |
NCT05909761 -
Observational Safety Study in Women With Neuromyelitis Optica Spectrum Disorder (NMOSD) Exposed to UPLIZNA® During Pregnancy
|
||
| Completed |
NCT02276963 -
Ublituximab for Acute Neuromyelitis Optica (NMO) Relapses
|
Phase 1 | |
| Terminated |
NCT04155424 -
A Study of the Safety and Activity of Eculizumab in Pediatric Participants With Relapsing Neuromyelitis Optica Spectrum Disorder
|
Phase 2/Phase 3 | |
| Completed |
NCT02003144 -
An Open Label Extension Trial of Eculizumab in Relapsing NMO Patients
|
Phase 3 |